A new JAMA Health Forum investigation reports that even as shortages for semaglutide and tirzepatide ease, compounded GLP-1 products continue to be produced using added ingredients, with supply and sourcing still evolving through the compounding ecosystem. The findings point to persistent variability in how patients access GLP-1 receptor agonists outside the brand pipeline. For clinicians and manufacturers, it raises new questions about consistency in product formulation, oversight, and continuity of supply as demand remains high.